Czech National Bank Purchases 26,627 Shares of Bristol Myers Squibb Company $BMY

Czech National Bank raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 4.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 581,252 shares of the biopharmaceutical company’s stock after buying an additional 26,627 shares during the quarter. Czech National Bank’s holdings in Bristol Myers Squibb were worth $33,492,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $25,000. Physician Wealth Advisors Inc. lifted its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. Bayban purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the fourth quarter valued at $32,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on BMY shares. Bank of America cut their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Wednesday. Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Raymond James Financial started coverage on shares of Bristol Myers Squibb in a report on Wednesday. They issued a “strong-buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades strengthen the outlook. Zacks upgraded BMY to Rank #2 (Buy), citing growing optimism about the company’s earnings prospects. Argus also raised its rating from “Hold” to “Buy” and set a $75 price target, implying further upside from recent levels. Bristol Myers Moves to Buy: Rationale Behind the Upgrade
• Positive Sentiment: Bristol Myers expanded its AI drug-discovery partnership with Schrödinger. Wider deployment of Schrödinger’s Bunsen and RetroSynth platforms across BMY’s research teams could improve drug-design efficiency and support the company’s longer-term pipeline, though the financial impact is not immediate. Schrödinger and BMS expand partnership
• Neutral Sentiment: Recent earnings momentum remains supportive. BMY previously reported earnings and revenue above analyst expectations, with revenue up year over year and full-year 2026 EPS guidance of $6.75-$7.00. This helps explain the stock’s strength and elevated investor interest.
• Neutral Sentiment: Alzheimer’s market developments offer limited direct benefit. The article highlights Leqembi and other disease-modifying therapies, but it does not identify a direct Bristol Myers product catalyst. Alzheimer’s Disease Market Pipeline Therapies
• Negative Sentiment: Merger speculation with AstraZeneca was denied. A senior source told Reuters there are “no discussions” regarding a potential transaction. That removes a possible takeover premium or strategic catalyst, although it also reduces uncertainty surrounding a major deal. No discussions over AstraZeneca-Bristol Myers deal

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $64.19 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a market cap of $131.13 billion, a P/E ratio of 14.14, a price-to-earnings-growth ratio of 0.16 and a beta of 0.22. The firm’s fifty day moving average price is $58.56 and its 200-day moving average price is $58.60.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the business earned $1.46 earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.97 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.